Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Heart Failure
Study data from Orion Pharma provide new insights into heart failure
May 13th, 2008
A new study, 'Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment,' is now available. According to recent research from Kuopio, Finland, "Levosimendan is a vasodilator used in the treatment of acute heart failure. In the present study, the effect of hepatic impairment on the pharmacokinetics of levosimendan and its 2 metabolites, OR-1855 and OR-1896 (pharmacologically active), was investigated in 12 healthy subjects and 12 subjects with moderate hepatic impairment due to alcoholic cirrhosis of the liver but with no heart failure." "In addition, the effect of acetylator status on the pharmacokinetics of levosimendan, OR-1855,...
Source: Cardiovascular Business Week (2008-05-13)
|
